← Back to Patent Explorer
US4601896A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical capsule compositions and structures for gastric sensitive materials

Assignee: Individual
•
Filing: 1984-03-21
•
Granted: 1986-07-22
•
Expires: 2004-03-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides oral dosage forms of therapeutic agents such as digestive enzymes which are subject to degradation and loss of activity at gastric pH. and compositions and methods for preparing same. Capsules of their components are formulated from a composition comprising a plastic homogeneous mass of gastric fluid impervious material such as cellulosic derivatives or collagenous material; from 10-65% by weight of a diluent selected from the group consisting of water, a lipid having a melting point above mammalian body temperature and a water miscible solvent; 4-60% by weight of procollagen; and 30-86% by weight of collagen or elastin. The composition is formed into finished capsules of relatively homogeneous composition comprising 10-50% by weight of procollagen and 40-96% by weight of a material selected from the group consisting of collagen and elastin, and having less than 4% by weight of fat and water-soluble protein. Prior art pH dependent enteric coat materials such as cellulose acetate phthalate may be incorporated at a level of 1.0-40%. At time of oral administration, an activator capable of dissolving the capsule wall is allowed to contact the interior surface of the capsule. In the case of cellulosic composition outer walls, cellulose or a non-enzymatic alkaline buffer is applied, and a proteolytic enzyme is employed to dissolve collagenous materials.

Inventors

  • 👤 Mark Nugent

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 03:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/4808; A61K9/4816; A61K9/4825; Y; Y10; Y10S; Y10S220/00; Y10S220/34; Y10S260/00; Y10S260/43

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 76 words
A pharmaceutical capsule blank adapted for oral administration of gastric-sensitive therapeutic agents, said capsule blank fabricated from a composition comprising a substantially homogeneous and gastric-fluid impervious composition comprising from about 10 to 50 percent by weight of procollagen, from about 40 to 96 percent by weight of at least one material selected from the group consisting of collagen and elastin, and less than 4 weight percent fat and albumin derived from said collagen or elastin source.
Claim 2
Dependent Claim 76 words
A pharmaceutical capsule blank adapted for oral administration of gastric-sensitive therapeutic agents, said capsule blank fabricated from a composition comprising a substantially homogeneous and gastric-fluid impervious composition comprising from about 10 to 50 percent by weight of procollagen, from about 40 to 96 percent by weight of at least one material selected from the group consisting of collagen and elastin, and less than 4 weight percent fat and albumin derived from said collagen or elastin source.
Claim 3
Dependent Claim 31 words
The capsule blank of claim 1, said blank including a chamber for containing a therapeutically effective amount of a gastric- sensitive medicament and a proteolytic enzyme capable of lysing said procollagen.
Claim 4
Dependent Claim 51 words
The capsule blank of claim 1, said blank including a first interior chamber for containing a therapeutically effective amount of a gastric-sensitive medicament and a second chamber adapted to releasably contain a material capable of dissolving the walls of said capsule blank when said material is released from said second chamber.
Claim 5
Dependent Claim 21 words
The capsule blank of claim 1 wherein said procollagen is present in an amount of from 10 to 20 weight percent.
Claim 6
Dependent Claim 102 words
A pharmaceutical capsule adapted for oral administration of a gastric-sensitive therapeutic agent, said capsule comprising an outer housing, said housing containing a first chamber, said first chamber filled with a therapeutically effective amount of said therapeutic agent; a second chamber, said second chamber containing an activator material capable of dissolving said capsule; said second chamber being contiguous to said housing, said housing comprising 10 to 50 percent by weight of procollagen, 40-96 weight percent of a material selected from the group consisting of collagen and elastin, and containing less than 4 weight percent fat or protein derived from said collagen or elastin.
Claim 7
Dependent Claim 102 words
A pharmaceutical capsule adapted for oral administration of a gastric-sensitive therapeutic agent, said capsule comprising an outer housing, said housing containing a first chamber, said first chamber filled with a therapeutically effective amount of said therapeutic agent; a second chamber, said second chamber containing an activator material capable of dissolving said capsule; said second chamber being contiguous to said housing, said housing comprising 10 to 50 percent by weight of procollagen, 40-96 weight percent of a material selected from the group consisting of collagen and elastin, and containing less than 4 weight percent fat or protein derived from said collagen or elastin.
Claim 8
Dependent Claim 46 words
The capsule of claim 5 wherein said housing is deformable whereby external deforming pressure may be applied to said capsule surface to cause rupturing of said second chamber, thereby allowing escape of said activator from said second chamber and contact of said activator with said housing.
Claim 9
Dependent Claim 18 words
The capsule of claim 5 wherein said activator material is a proteolytic enzyme capable of lysing said procollagen.
Claim 10
Dependent Claim 20 words
The capsule of claim 5 wherein said housing additionally comprises from 15 to 35 weight percent of cellulose acetate phthalate.
Claim 11
Dependent Claim 61 words
A composition of matter suitable for fabrication into housings for oral unit dosage forms of gastric-sensitive medicaments comprising: a plastic homogeneous mass of from 40 to 96 weight percent of collagen or elastin having substantially all naturally occurring lipids and water-soluble protein removed therefrom; from about 10-50 weight percent of procollagen; and sufficient diluent to render said mass pliable for fabrication.
Claim 12
Dependent Claim 61 words
A composition of matter suitable for fabrication into housings for oral unit dosage forms of gastric-sensitive medicaments comprising: a plastic homogeneous mass of from 40 to 96 weight percent of collagen or elastin having substantially all naturally occurring lipids and water-soluble protein removed therefrom; from about 10-50 weight percent of procollagen; and sufficient diluent to render said mass pliable for fabrication.
Claim 13
Dependent Claim 37 words
The composition of claim 9 additionally comprising from 1.0% to 40% by weight of pH dependant non-collagenous enteric pharmaceutically acceptable coat composition, provided that the procollagen level is 10% to 50% by weight of the total composition.
Claim 14
Dependent Claim 29 words
The composition of claim 9 additionally comprising from 15% to 35% by weight of cellulose acetate phthalate, provided the procollagen content is 10% to 50% of the total weight.
Claim 15
Dependent Claim 85 words
A pharmaceutical oral unit dosage form for administering gastric-sensitive materials to a mammalian host comprising: a capsule having a resilient outer wall which is impervious to gastric fluids, said outer wall defining a first chamber adapted to house a therapeutically effective amount of a gastric sensitive medicament; said unit dosage form further including pharmaceutically acceptable activator fluid contained within said capsule, said fluid causing digestion of said capsule wall on a timed basis so as to release said gastric-sensitive medicament into the lower intestinal tract.
Claim 16
Dependent Claim 85 words
A pharmaceutical oral unit dosage form for administering gastric-sensitive materials to a mammalian host comprising: a capsule having a resilient outer wall which is impervious to gastric fluids, said outer wall defining a first chamber adapted to house a therapeutically effective amount of a gastric sensitive medicament; said unit dosage form further including pharmaceutically acceptable activator fluid contained within said capsule, said fluid causing digestion of said capsule wall on a timed basis so as to release said gastric-sensitive medicament into the lower intestinal tract.
Claim 17
Dependent Claim 30 words
The unit dosage form of claim 12 wherein said chamber is filled with said gastric sensitive medicament and said pharmaceutically acceptable activator fluid immediately prior to administration of said capsule.
Claim 18
Dependent Claim 37 words
The unit dosage form of claim 12 wherein said capsule further comprises a second chamber, said second chamber housing said pharmaceutically acceptable activator fluid which is released into said first chamber when said second chamber is ruptured.
Claim 19
Dependent Claim 31 words
The unit dosage form of claim 14 wherein said second chamber is defined by a brittle wall capable of rupturing when external deforming pressure is applied to said resilient capsule wall.
Claim 20
Dependent Claim 51 words
A pharmaceutically acceptable oral unit dosage composition which is substantially homogeneous and gastric-fluid impervious comprising from about 10% to 50% procollagen by weight and at least 40% by weight of at least one material selected from the group consisting of collagen and elastin, substantially free of native fat and water-soluble protein.
Claim 21
Dependent Claim 51 words
A pharmaceutically acceptable oral unit dosage composition which is substantially homogeneous and gastric-fluid impervious comprising from about 10% to 50% procollagen by weight and at least 40% by weight of at least one material selected from the group consisting of collagen and elastin, substantially free of native fat and water-soluble protein.
Claim 22
Independent Claim 66 words
A method of administering a therapeutically effective amount of a gastric-sensitive medicament to a patient in need of said treatment comprising orally administering said medicament to said patient in a housing which is impervious to gastric fluid, said unit dosage form including an activator which dissolves said housing at a pre-determined time so as to predictably release said medicament into the intestinal tract of said patient.
Claim 23
Independent Claim 66 words
A method of administering a therapeutically effective amount of a gastric-sensitive medicament to a patient in need of said treatment comprising orally administering said medicament to said patient in a housing which is impervious to gastric fluid, said unit dosage form including an activator which dissolves said housing at a pre-determined time so as to predictably release said medicament into the intestinal tract of said patient.
Claim 24
Dependent Claim 21 words
The method of claim 17 wherein said medicament and said pharmaceutically acceptable activator are introduced into said housing immediately before administration.
Claim 25
Dependent Claim 91 words
The method of claim 17 wherein said medicament and said pharmaceutically acceptable activator are present in a finished unit dosage form, said unit dosage form comprising a housing which includes a first chamber and a second chamber, said first chamber containing said medicament and said second chamber containing said activator, said activator being released when pressure is applied to said unit dosage form so as to rupture a wall of said second chamber thereby releasing activator whereby said activator contacts and dissolves said housing, releasing medicament into said patient's intestinal tract.

References Cited (Backward Citations)

CH183805A Cited
US2340037A Cited
US2491475A Cited
US3655035A Cited
US3655416A Cited
US3806350A Cited
US3955697A Cited
DE2729068A1 Cited
DE2729007A1 Cited
US4428927A Cited
US4427116A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-07-21 1990-01-20 1990-07-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-07-21 1994-01-20 1994-07-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-07-21 1998-01-20 1998-07-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag